Budget Amount *help |
¥56,900,000 (Direct Cost: ¥56,900,000)
Fiscal Year 2009: ¥11,400,000 (Direct Cost: ¥11,400,000)
Fiscal Year 2008: ¥11,400,000 (Direct Cost: ¥11,400,000)
Fiscal Year 2007: ¥11,400,000 (Direct Cost: ¥11,400,000)
Fiscal Year 2006: ¥11,400,000 (Direct Cost: ¥11,400,000)
Fiscal Year 2005: ¥11,300,000 (Direct Cost: ¥11,300,000)
|
Research Abstract |
The role of vasohibin-1(VASH-1), a negative feedback regulator of angiogenesis synthesized by endothelial cells(ECs), and vasohibin-2(VASH-2) which antagonizes VASH-1 was studied. Pathological analysis revealed that VASH-1 was present in ECs in tumor vessels, which was correlated with VEGF in cancer cells, pathological grading, and proliferation rate of cancer cells. Animal models revealed that endogenous VASH-1 regulates tumor angiogenesis, but exogenous supplementation of VASH-1 further exhibited anti-angiogenic and anti-lymphangiogenic activities and inhibited tumor growth and lymph node metastasis. VASH-2 was shown in mononuclear cells infiltrating in cancer stroma as well as in cancer cells, and VASH-2 promoted tumor growth by stimulating angiogenesis.
|